Abstract
Thalidomide is reported to be effective to advanced renal cell carcinoma (RCC) for not only single use but also combination with other agents. The purpose of this study was to determine the efficacy and safety profile of thalidomide with interleukin-2 (IL-2) in metastatic RCC (MRCC) patients who were refractory to prior cytokine therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
